Prevalence Based Adjustment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Business Wire. The AP news staff was not involved in its creation.
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
February 11, 2021 GMT
CAMBRIDGE, Mass. (BUSINESS WIRE) Feb 11, 2021
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2020 and reviewed recent business highlights.
“We’re very pleased with the 2020 commercial performance for our marketed products, and expect steady and continued growth in 2021 across our product portfolio, driven by improved disease awareness, new patient finding, and geographic expansion. In the fourth quarter we celebrated the regulatory approvals of our third and fourth commercial medicines: OXLUMO, in the EU and U.S.; and Leqvio, in the EU. We also reported positive topline results fro ....

United States , United Kingdom , Josh Brodsky , Agnieszka Gallagher , Kasha Witkos , John Maraganore , Salil Patel , Jeff Poulton , Tolga Tanguler , Head Of Medical Affairs , Research Development , Alnylam Pharmaceuticals Inc , Alnylam Pharmaceuticals , Alnylam Pharmaceuticals Inc Christine Regan Lindenboom , Exchange Commission , European Union , American Academy Of Neurology , Blackstone Group Inc , Chief Executive Officer , Recent Significant Corporate , Temporary Authorization , Patient Need Adjustment , Prevalence Based Adjustment , New Drug Application , European Commission , Complete Response Letter ,